Transforming genomic grade index (GGI) into a user-friendly qRT-PCR tool which will assist clinicians and patients in optimizing treatment of early breast cancer (BC) No significant financial ...
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been ...
Good morning, and welcome to the IDEAYA Biosciences webcast. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the IDEAYA Biosciences website ...
Hemapoietic, immunomodulatory, antitumor, and toxicity profiles of sequential GM-CSF and IFNγ1b biotherapy and carboplatin in recurrent ovarian carcinoma No significant financial relationships to ...
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full ...
Reprogramming human regulatory T cell specificity with a novel anti-HLA-A2 chimeric antigen receptor
Engineering human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting donor-derived human leukocyte antigen (HLA) is a promising strategy to induce immune tolerance to ...
A major hurdle for using engineered CAR-T cells to treat solid tumors is the lack of tumor-specific markers for therapies to target. By leveraging a unique genetic feature that separates tumors from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results